Skip to main content
SpringerLink
Log in

A Tail with a Thorn in it: Second-Generation Antipsychotics Hand in Hand with Statins

  • Invited Commentary
  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Health Niom. Schizophrenia. Available at: http://www.nimh.nih.gov/statistics/1SCHIZ.shtml. Accessed 15 April 2012.

  2. Tandon R. Antipsychotics in the treatment of schizophrenia: an overview. J Clin Psychiatry. 2011;72 Suppl 1:4–8.

    Article  PubMed  CAS  Google Scholar 

  3. Miyamoto S, Duncan GE, Marx CE, Lieberman JA. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2004;10:79–104.

    Article  Google Scholar 

  4. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209–23.

    Article  PubMed  CAS  Google Scholar 

  5. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St. Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950–2005. Schizophr Res. 2008;98:287–94.

    Article  PubMed  Google Scholar 

  6. J. Parks DS, Singer P, Foti M. Morbidity and mortality in people with serious mental illness.National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council, Alexandria, VA 22314. 2006. Available at: http://www.nasmhpd.org/general_files/publications/med_directors_pubs/Technical%20Report%20on%20Morbidity%20and%20Mortaility%20-%20Final%2011-06.pdf. Accessed 15 April 2012.

  7. Tsuang MT. Suicide in Schizophrenics, manics, depressives, and surgical controls: a comparison with general population suicide mortality. Arch Gen Psychiatry. 1978;35:153–5.

    Article  PubMed  CAS  Google Scholar 

  8. Tsuang MT, Woolson RF, Fleming JA. Premature deaths in schizophrenia and affective disorders: an analysis of survival curves and variables affecting the shortened survival. Arch Gen Psychiatry. 1980;37:979–83.

    Article  PubMed  CAS  Google Scholar 

  9. de Leon J, Diaz FJ. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res. 2005;76:135–57.

    Article  PubMed  Google Scholar 

  10. Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr Res. 2005;79:323–35.

    Article  PubMed  Google Scholar 

  11. Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, et al. A comparison of 10-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45–53.

    Article  PubMed  Google Scholar 

  12. Breier A, Berg PH, Thakore JH, Naber D, Gattaz WF, Cavazzoni P, et al. Olanzapine vs ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry. 2005;162:1879–87.

    Article  PubMed  Google Scholar 

  13. Schoemaker J, Naber D, Vrijland P, Panagides J, Emsley R. Long-term assessment of asenapine vs olanzapine in patients with schizophrenia or schizoaffective disorder. Pharmacopsychiatry. 2010;43:138–46.

    Article  PubMed  CAS  Google Scholar 

  14. Grootens KP, van Veelen NM, Peuskens J, Sabbe BG, Thys E, Buitelaar JK, et al. Ziprasidone vs olanzapine in recent-onset schizophrenia and schizoaffective disorder: results of an 8-week double-blind randomized controlled trial. Schizophr Bull. 2011;37:352–61.

    Article  PubMed  CAS  Google Scholar 

  15. Merck Pulls Arthritis Drug Vioxx from Market NPR; 2004. Available at: http://www.npr.org/templates/story/story.php?storyId=4054991. Accessed 15 April 2012.

  16. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343:1520–8.

    Article  PubMed  CAS  Google Scholar 

  17. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092–102.

    Article  PubMed  CAS  Google Scholar 

  18. Rofecoxib. Wikipedia; 2009. Available at: http://en.wikipedia.org/wiki/Rofecoxib. Accessed 15 April 2012.

  19. Smith Jr SC, Benjamin EJ, Bonow RO, Braun LT, Creager MA, Franklin BA, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol. 2011;58:2432–46.

    Article  PubMed  Google Scholar 

Download references

Disclosure

R. Durtst: none. E. Leitersdorf: Board membership, consultancy and honoraria received from Roche, Merck, and Novartis, payment for the development of educational presentations from Roche and Merck.

Author information

Authors and Affiliations

  1. Center for Research Prevention and Treatment of Atherosclerosis, Hadassah Hebrew University Medical Center, Jerusalem, Israel

    Ronen Durst & Eran Leitersdorf

  2. Cardiology Department, Hadassah Hebrew University Medical Center, Jerusalem, Israel

    Ronen Durst

Authors
  1. Ronen Durst
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eran Leitersdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eran Leitersdorf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Durst, R., Leitersdorf, E. A Tail with a Thorn in it: Second-Generation Antipsychotics Hand in Hand with Statins. Curr Atheroscler Rep 14, 391–393 (2012). https://doi.org/10.1007/s11883-012-0262-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-012-0262-z

Keywords

Search

Navigation